Insider Transactions in Q4 2016 at Crispr Therapeutics Ag (CRSP)
Insider Transaction List (Q4 2016)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 24
2016
|
Sven Ante Lundberg Chief Scientific Officer |
BUY
Open market or private purchase
|
Indirect |
400
+0.08%
|
$5,600
$14.0 P/Share
|
|
Oct 24
2016
|
Sven Ante Lundberg Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
55,217
+9.85%
|
-
|
|
Oct 24
2016
|
Kurt Von Emster Director |
BUY
Open market or private purchase
|
Indirect |
56,000
+2.11%
|
$784,000
$14.0 P/Share
|
|
Oct 24
2016
|
Kurt Von Emster Director |
BUY
Conversion of derivative security
|
Indirect |
2,545,814
+28.5%
|
-
|
|
Oct 24
2016
|
Bradley J Ph D Bolzon Director |
BUY
Conversion of derivative security
|
Indirect |
6,508,699
+29.95%
|
-
|
|
Oct 24
2016
|
Bradley J Ph D Bolzon Director |
BUY
Open market or private purchase
|
Indirect |
161,000
+2.38%
|
$2,254,000
$14.0 P/Share
|
|
Oct 24
2016
|
Thomas Woiwode Director |
BUY
Conversion of derivative security
|
Indirect |
6,508,699
+29.95%
|
-
|
|
Oct 24
2016
|
Thomas Woiwode Director |
BUY
Open market or private purchase
|
Indirect |
161,000
+2.38%
|
$2,254,000
$14.0 P/Share
|
|
Oct 24
2016
|
Celgene Corp /De/ > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,150
+14.2%
|
$11,202,100
$14.0 P/Share
|
|
Oct 24
2016
|
Celgene Corp /De/ > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,034,830
+50.0%
|
-
|
|
Oct 24
2016
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
66,500
+2.02%
|
$931,000
$14.0 P/Share
|
|
Oct 24
2016
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,154,127
+28.14%
|
-
|
|
Oct 24
2016
|
Simeon George |
BUY
Open market or private purchase
|
Indirect |
66,500
+2.02%
|
$931,000
$14.0 P/Share
|
|
Oct 24
2016
|
Simeon George |
BUY
Conversion of derivative security
|
Indirect |
3,154,127
+28.14%
|
-
|
|
Oct 24
2016
|
Versant Venture Capital Iv, L.P. > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
161,000
+2.38%
|
$2,254,000
$14.0 P/Share
|
|
Oct 24
2016
|
N Anthony Coles Director |
BUY
Grant, award, or other acquisition
|
Indirect |
70,000
+33.33%
|
$980,000
$14.0 P/Share
|
|
Oct 24
2016
|
Hadley Harbor Master Investors (Cayman) L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
744,380
+50.0%
|
-
|